Evidence map›Paper›PMID 41847658›Full record

ReviewACS medicinal chemistry letters2026

Molecular Basis of c‑MET Inhibition by Approved Small Molecule Drugs: A Structural Perspective.

Isabella C Russell, Paulina Bachurska-Szpala, Lotte van Beek, Iacovos N Michaelides, Christopher Phillips, Arjan Snijder, Christopher J Stubbs, Gavin W Collie

Abstract readReview
In one paragraph

Review in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Discovery of 2H-Pyrrolo[3,4‑ACS medicinal chemistry letters · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Isabella C RussellDiscovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Paulina Bachurska-SzpalaFaculty of Chemistry, University of Warsaw, Warsaw 02-093, Poland.
Lotte van BeekDiscovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Iacovos N MichaelidesDiscovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.ORCID https://orcid.org/0000-0001-6993-6788
Christopher PhillipsDiscovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Arjan SnijderDiscovery Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden.
Christopher J StubbsDiscovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Gavin W CollieDiscovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.ORCID https://orcid.org/0000-0002-0406-922X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The c-MET kinase is a driver of many cancers, and as such, there are a number of small molecule inhibitors of this kinase approved for clinical use. In this Microperspective, we provide a structural overview of the molecular basis by which these drugs inhibit c-MET, focusing on key features contributing to activity, selectivity, and drug resistance. Where necessary, relevant crystal structures not publicly available were determined and are discussed here alongside existing structural data.

Indexed as

c-METkinase inhibitornon-small cell lung cancerNSCLCsmall molecule drug

Identifiers

PMID41847658
PMCPMC12989872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.